Abstract
Belantamab mafodotin (belamaf) and melphalan flufenamide in combination with dexamethasone (MEL+DEX) have been approved for heavily pretreated relapsed/refractory multiple myeloma (RRMM) patients. Hefty price tags of each highlight the need to evaluate the relationship between the costs and outcomes achieved by these therapies. The objective of the research is to evaluate the cost-effectiveness of belamaf compared with MEL+DEX in RRMM patients who have received at least four prior lines of therapy from a U.S. commercial payer perspective.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
